MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Eli Lilly discontinues Ypsomed collaboration to pursue its own U.S. insulin pump offering

Eli Lilly discontinues Ypsomed collaboration to pursue its own U.S. insulin pump offering

By

Ypsomed Eli LillyYpsomed announced today that Eli Lilly (NYSE:LLY) elected to stop their joint project to enter the U.S. insulin pump market.

In November 2020, the companies entered into a commercialization agreement. The agreement entailed registering and commercializing Ypsomed’s YpsoPump under Lilly’s branding in the U.S. Ypsomed said that, over the past two years, it customized its pump for the U.S. market in preparation for commercialization. Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016.

Get the full story at our sister site, Drug Delivery Business News.

More recent news

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].